High sensitive thyroglobulin assay on thyroxine therapy: Can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?

Hormone and Metabolic Research

Volumn 45, Issue 9, 2013, Pages 664-668

  Trimboli, P ^a   La Torre, D ^a   Ceriani, L ^b   Condorelli, E ^a   Laurenti, O ^a   Romanelli, F ^c   Ventura, C ^a   Signore, A ^d   Valabrega, S ^e   Giovanella, L ^b  

^a Piazza San Bartolomeo All'Isola 21   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

thyroglobulin; thyroid carcinoma; ultrasound; whole body scan

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; THYROXINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; THYROGLOSSAL DUCT CYST;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THYROGLOBULIN; THYROID FUNCTION TESTS; THYROID NEOPLASMS; THYROXINE; TREATMENT OUTCOME;

EID: 84882916791     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0033-1345185     Document Type: Article

References (24)

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Pacini F., Schlumberger M., Sherman S. I., Steward D. L., Tuttle R. M. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: 2009; 19 1167 1214
2. Gharib H., Papini E., Paschke R., Duick D. S., Valcavi R., Hegedüs L., Vitti P. AACE/AME/ETA Task Force on Thyroid Nodules American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest: 2010; 33 287 291
3. Chianelli M., Todino V., Graziano F. M., Panunzi C., Pace D., Guglielmi R., Signore A., Papini E. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol: 2009; 160 431 436
4. Schlumberger M., Hitzel A., Toubert M. E., Corone C., Troalen F., Schlageter M. H., Claustrat F., Koscielny S., Taieb D., Toubeau M., Bonichon F., Borson-Chazot F., Leenhardt L., Schvartz C., Dejax C., Brenot-Rossi I., Torlontano M., Tenenbaum F., Bardet S., Bussière F., Girard J. J., Morel O., Schneegans O., Schlienger J. L., Prost A., So D., Archambeaud F., Ricard M., Benhamou E. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab: 2007; 92 2487 2495 (Pubitemid 47037347)
5. Smallridge R. C., Meek S. E., Morgan M. A., Gates G. S., Fox T. P., Grebe S., Fatourechi V. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab: 2007; 92 82 87 (Pubitemid 46075007)
6. Malandrino P., Latina A., Marescalco S., Spadaro A., Regalbuto C., Fulco R. A., Scollo C., Vigneri R., Pellegriti G. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab: 2011; 96 1703 1709
7. Iervasi A., Iervasi G., Ferdeghini M., Solimeo C., Bottoni A., Rossi L., Colato C., Zucchelli G. C. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf): 2007; 67 434 441 (Pubitemid 47283844)
8. Spencer C., Fatemi S., Singer P., Nicoloff J., Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid: 2010; 20 587 595
9. Chindris A. M., Diehl N. N., Crook J. E., Fatourechi V., Smallridge R. C. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab: 2012; 97 2714 2723
10. Giovanella L., Ceriani L., Ghelfo A., Keller F., Sacchi A., Maffioli M., Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med: 2006; 44 648 652 (Pubitemid 43735641)
11. Giovanella L., Ceriani L. High-sensitivity human thyroglobulin (hTG) imunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med: 2002; 40 480 484 (Pubitemid 34693089)
12. Rosario P. W., Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf): 2008; 68 338 342 (Pubitemid 351257849)
13. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J. W., Wiersinga W. European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol: 2006; 154 787 803 (Pubitemid 43997716)
14. Giovanella L., Ceriani L., De Palma D., Suriano S., Castellani M., Verburg F. A. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinoma. Head Neck: 2012; 34 626 631
15. Baloch Z., Carayon P., Conte-Devolx B., Demers L. M., Feldt-Rasmussen U., Henry J. F., LiVolsi V. A., Niccoli-Sire P., John R., Ruf J., Smyth P. P., Spencer C. A., Stockigt J. R. Guidelines Committee, National Academy of Clinical Biochemistry Laboratory medicine practice guidelines Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid: 2003; 13 3 126
16. Mazzaferri E. L. Will highly sensitive thyroglobulin assays change the management of thyroid cancer? Clin Endocrinol (Oxf): 2007; 67 321 323 (Pubitemid 47283837)
17. Spencer C. A., Lopresti J. S. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab: 2008; 4 223 233 (Pubitemid 351430907)
18. Pacini F., Molinaro E., Lippi F., Castagna M. G., Agate L., Ceccarelli C., Taddei D., Elisei R., Capezzone M., Pinchera A. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab: 2001; 86 5686 5690 (Pubitemid 33152608)
19. Haugen B. R., Pacini F., Reiners C., Schlumberger M., Ladenson P. W., Sherman S. I., Cooper D. S., Graham K. E., Braverman L. E., Skarulis M. C., Davies T. F., DeGroot L. J., Mazzaferri E. L., Daniels G. H., Ross D. S., Luster M., Samuels M. H., Becker D. V., Maxon H. R. 3rd, Cavalieri R. R., Spencer C. A., McEllin K., Weintraub B. D., Ridgway E. C. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab: 1999; 84 3877 3885 (Pubitemid 30644169)
20. Ronga G., Filesi M., Ventroni G., Vestri A. R., Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med: 1999; 26 1448 1452 (Pubitemid 29515606)
21. Filesi M., Signore A., Ventroni G., Melacrinis F. F., Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med: 1998; 39 1542 1546 (Pubitemid 28459883)
22. Ronga G., Fiorentino A., Paserio E., Signore A., Todino V., Tummarello M. A., Filesi M., Baschieri I. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med: 1990; 31 1766 1771 (Pubitemid 20374507)
23. Golger A., Fridman T. R., Eski S., Witterik I. J., Freeman J. L., Walfish P. G. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest: 2003; 26 1023 1031 (Pubitemid 38049156)
24. Davis T., Witterik I. J., Spiro E., Walfish P. G., Freeman J. L. Three-Week Thyroxine Withdrawal: A Thyroid-Specific Quality of Life Study. Laryngoscope: 2006; 116 250 253 (Pubitemid 44383933)